We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Biocept Inc (BIOC) USD0.0001

Sell:$2.65 Buy:$2.73 Change: $0.04 (1.50%)
Market closed |  Prices as at close on 28 January 2022 | Switch to live prices |
Change: $0.04 (1.50%)
Market closed |  Prices as at close on 28 January 2022 | Switch to live prices |
Change: $0.04 (1.50%)
Market closed |  Prices as at close on 28 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biocept, Inc. is an early stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor nucleic acid, including circulating tumor deoxyribonucleic acid (ctDNA) and circulating tumor ribonucleic acid (ctRNA), assays using a standard blood sample or liquid biopsy. Its blood and cerebrospinal fluid (CSF) assays are intended to provide information to aid healthcare providers by identifying tumor cells associated with progression or metastasis and identifying specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy. The Company's Target-Selector CTC and molecular platforms provide both biomarker detection as well as monitoring capabilities and require only a patient blood sample or CSF sample to inform treatment decisions. It also offers sensitive polymerase chain reaction (PCR) based assay through Aegea Biotechnologies, Inc. (Aegea) for detecting the COVID-19 virus.

Contact details

9955 Mesa Rim Road
United States
+1 (858) 3208200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$48.17 million
Shares in issue:
16.84 million
United States
US dollar

Key personnel

  • Samuel Riccitelli
    Chairman of the Board
  • Michael Nall
    President, Chief Executive Officer, Director
  • Timothy Kennedy
    Chief Financial Officer, Chief Operating Officer, Corporate Secretary
  • Michael Dugan
    Senior Vice President, Chief Medical Officer and Medical Director
  • Michael Terry
    Senior Vice President - Corporate Development
  • Michael Brown
    General Counsel, Compliance and Privacy Officer
  • Antonio Paternostro
    Vice President - Sales
  • Gary Marchetti
    Senior Director - People and Culture / Facilities
  • Tom Nauman
    Senior Director - Quality
  • Tim Schofield
    Senior Director - Product Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.